All In Biotech

Drug Trial Radar · NCT01371981

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,645 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,645

Actual

Start

Jul 6, 2011

Primary completion

Mar 31, 2019

Study completion Mar 31, 2026

Sponsor

Sponsor type
NIH
First posted
Jun 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Conditions

  • Acute Myeloid Leukemia
  • Leukemia Cutis
  • Myeloid Neoplasm
  • Myeloid Sarcoma

Interventions

  • AsparaginaseDrug

    Given IM

  • BortezomibDrug

    Given IV

  • CytarabineDrug

    Given IT or IV

  • Daunorubicin HydrochlorideDrug

    Given IV

  • EtoposideDrug

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Mitoxantrone HydrochlorideDrug

    Given IV

  • Pharmacological StudyOther

    Correlative studies

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Sorafenib TosylateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ MutationsTime frame: Up to 3 years
  2. EFS for Patients on Arm C, Cohort 1Time frame: Up to 3 years
  3. EFS for Patients on Arm C, Cohort 2Time frame: Up to 3 years
  4. EFS for Patients on Arm C, Cohort 3Time frame: Up to 3 years

Locations

220 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • USA Health Strada Patient Care Center

    Mobile, Alabama

  • Banner Children's at Desert

    Mesa, Arizona

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Kaiser Permanente Downey Medical Center

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Miller Children's and Women's Hospital Long Beach

    Long Beach, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Valley Children's Hospital

    Madera, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Lucile Packard Children's Hospital Stanford University

    Palo Alto, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Santa Barbara Cottage Hospital

    Santa Barbara, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

    Denver, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Yale University

    New Haven, Connecticut

  • Alfred I duPont Hospital for Children

    Wilmington, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Lee Memorial Health System

    Fort Myers, Florida

  • Golisano Children's Hospital of Southwest Florida

    Fort Myers, Florida

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital

    Hollywood, Florida

  • Nemours Children's Clinic-Jacksonville

    Jacksonville, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.